Compounded sulfamethoxazole improved the prognosis of dermatomyositis patients positive with anti-melanoma differentiation-associated gene 5
Main finding · PJP incidenceResult — go to the resultAdjusted odds ratio 0.299 95% CI 0.102–0.878Authors' conclusion
Prophylactic use of coSMZ is an effective and safe way to improve the prognosis of anti-MDA5-DM patients by preventing the incidence of PJP.
Study context
- Population
- Consecutive patients with new-onset anti-MDA5-DM, June 2018 to October 2021, single centre
- Participants
- 121 vs 93
- Exposure
- Initial prophylactic compounded sulfamethoxazole (coSMZ) vs no prophylactic coSMZ
- coSMZn = 121
- non-coSMZn = 93reference
- Outcome
- Incidence of Pneumocystis jirovecii pneumonia (PJP)
- Follow-up
- 12 months
Methodological detailssingle-centre, consecutive patients, adjusted for age, gender, disease duration, peripheral blood lymphocyte count, anti-MDA5 antibody titres, ground-glass opacity scores and treatments
- Single-centre
- Consecutive patients
- Adjusted for age, gender, disease duration, peripheral blood lymphocyte count, anti-MDA5 antibody titres, ground-glass opacity scores and treatments
Main finding
PJP incidence · first 12 months from diagnosis
Adjusted odds ratio
0.299
95% CI 0.102–0.878
P = 0.028
By group
coSMZvs non-coSMZ
aOR 0.299 (95% CI 0.102–0.878); P = 0.028
As reported in the abstract
Observational data: associations, not effects.
Further findings
Mortality · first 12 months from diagnosis
P < 0.001
Fatal infection · first 12 months from diagnosis · described as lower in the coSMZ group; values as printed
P = 0.001
Original publication
Compounded sulfamethoxazole improved the prognosis of dermatomyositis patients positive with anti-melanoma differentiation-associated gene 5. Rheumatology (Oxford). Published 25 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →